# Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

> **NCT02874326** · PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Gastrointestinal Hemorrhage
- Anemia

## Interventions

- **DRUG:** Octreotide LAR

## Key facts

- **NCT ID:** NCT02874326
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-07
- **Final completion:** 2018-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874326, "Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02874326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*